This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast And Market Analysis Event-Driven Update

NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

http://www.reportlinker.com/p01084939/PharmaPoint-Rheumatoid-Arthritis---India-Drug-Forecast-and-Market-Analysis-Event-Driven-Update.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

Summary

GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Indian physicians included in our study typically follow guidelines such as ACR or EULAR, but also follow their own clinical experience. In India, the process to diagnosis a patient with RA usually begins with the PCP or GP regardless of which potential stage the patient is in, then progresses with the referral to a rheumatologist for further diagnosis and treatment as this occurs about 32% of the time. Also, most people seeking treatment are within the 35-55-year-old group. Within this age group, females and males are equally distributed according to our physician experts.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in India from 2011 to 2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the India rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs